CIK 0000879407
- Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460408024
- Phone
- +1 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −7,416 | $65.88 | $489K | 3,798,510 |
| 2026-01-02 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −5,771 | $66.39 | $383K | 3,792,739 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 | +35,181 | $6.15 | $216K | 3,841,107 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 | +16,545 | $6.15 | $102K | 3,857,652 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −35,181 | $69.33 | $2.4M | 3,822,471 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −16,545 | $68.69 | $1.1M | 3,805,926 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −35,181 | 16,545 | ||
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −16,545 | 0 | ||
| 2025-12-22 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −10,012 | $68.33 | $684K | 3,808,500 |
| 2025-12-22 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −2,574 | $68.85 | $177K | 3,805,926 |
| 2025-12-19 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −3,979 | $66.67 | $265K | 3,827,978 |
| 2025-12-19 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −8,147 | $68.01 | $554K | 3,819,831 |
| 2025-12-19 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −1,319 | $68.48 | $90K | 3,818,512 |
| 2025-12-17 | Anzalone Christopher Richard Chief Executive Officer | Sale | −46,287 | $63.55 | $2.9M | 3,870,670 |
| 2025-12-17 | Anzalone Christopher Richard Chief Executive Officer | Sale | −35,750 | $64.51 | $2.3M | 3,834,920 |
| 2025-12-17 | Anzalone Christopher Richard Chief Executive Officer | Sale | −982 | $65.53 | $64K | 3,833,938 |
| 2025-12-17 | Anzalone Christopher Richard Chief Executive Officer | Sale | −1,981 | $66.30 | $131K | 3,831,957 |
| 2025-12-16 | Anzalone Christopher Richard Chief Executive Officer | Sale | −8,416 | $60.51 | $509K | 3,962,839 |
| 2025-12-16 | Anzalone Christopher Richard Chief Executive Officer | Sale | −10,963 | $61.25 | $671K | 3,951,876 |
| 2025-12-16 | Anzalone Christopher Richard Chief Executive Officer | Sale | −14,095 | $62.12 | $876K | 3,937,781 |
Page 1 of 10 · 195 trades